Leader Capital Markets Remains a Buy on Teva (TEVA)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Levi is ranked #6867 out of 9595 analysts.
The analyst consensus on Teva is currently a Hold rating.
Based on Teva's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of ILA3.89 billion and a net profit of ILA214 million. In comparison, last year the company earned a revenue of ILA3.82 billion and had a GAAP net loss of ILA139 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Teva Pharmaceutical Industries TEVA reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the Zacks Consensus Estimate of 63 cents. Adjusted earnings rose 8% year over year, driven by higher operating profits. Revenues for the second quarter were $4.18 billion, which missed the Zacks Consensus Estimate of $4.28 billion. Total revenues were flat year over year on a reported basis and down 1% on a constant currency basis. Revenue growth suffered as the gains from the increasing sales of its branded drugs, Austedo, Ajovy, and Uzedy, were offset by lower generic drug sales in Teva's U.S. and international markets, mainly resulting from its exit from Japan. Branded Products Drive TEVA's US Unit's Sales Sales in the United States segment were $2.15 billion, up 2% year over year, driven by higher revenues from Teva's branded drugs, Ajovy, Austedo and Uzedy, partially offset by a decline in generic revenues. The segment's sales missed the Zacks Consensus Estimate of $2.19 billion but beat our model estimate of $2.11 billion. Generic/biosimilar product revenues declined 6% from the year-ago period to $961 million in the United States due to lower revenues from the generic versions of Revlimid and Victoza. Generic revenues missed the Zacks Consensus Estimate of $1.05 billion as well as our model estimate of $1.02 billion. Teva's ne generic drugs includes Simlandi, a generic version of AbbVie's ABBV Humira, which was approved in February 2024 and launched in May. Teva also has other high-value complex generics like Selarsdi. Notably, Selarsdi is a biosimilar version of J&J's JNJ Stelara, which was approved in April 2024 and launched in February 2025, per settlement terms with J&J. Simlandi and Selarsdi are the first two biosimilars to launch in the United States under the Teva and Alvotech strategic partnership, which includes nine products. Teva and partner Samsung Bioepis' Epysqli, a biosimilar version of AstraZeneca's Soliris, was launched in the United States in early April. Teva entered into a strategic partnership with Samsung Bioepis in January 2025 for the commercialization of Epysqli in the United States. So far this year, shares of TEVA have plunged 23.6% compared with the industry's decline of 9.8%. Image Source: Zacks Investment Research Huntington's disease drug, Austedo, recorded sales of $495 million in the United States, up 22% year over year. Sales were mainly driven by volume growth as prescription trends continued to grow. Austedo sales missed the Zacks Consensus Estimate of $501.7 million while marginally beating our model estimate of $494.8 million. Ajovy recorded sales of $63 million in the quarter, up 53% year over year, driven by volume growth. Ajovy sales surpassed the Zacks Consensus Estimate of $50.8 million as well as our model estimate of $42.6 million. Uzedy (risperidone), a long-acting subcutaneous atypical antipsychotic injection for the treatment of schizophrenia, generated sales of $54 million in the second quarter, up 120% year over year, mainly driven by volume growth. Copaxone recorded sales of $62 million in the United States, down 23% year over year, mainly due to market share erosion and competition. Copaxone sales beat the Zacks Consensus Estimate of $48.8 million as well as our model estimate of $45.8 million. Performance of TEVA's Europe and International Market Units The Europe segment recorded revenues of $1.3 billion, up 7% year over year on a reported basis. Sales were up 3% on a constant currency basis, mainly driven by the sale of certain product rights, higher revenues from Ajovy and generic products. Europe revenues beat the Zacks Consensus Estimate as well as our model estimate of $1.25 billion. In the International Markets segment, sales declined 17% year over year to $495 million. In constant currency terms, sales decreased 16% year over year, mainly due to the divestment of Teva's business venture in Japan. International Markets revenues missed the Zacks Consensus Estimate of $602.4 million as well as our model estimate of $651.3 million. The Other segment (comprising the sales of active pharmaceutical ingredients to third parties and certain contract manufacturing services) recorded revenues of $232 million, down 7% year over year on a reported basis and down 9% year over year on a constant currency basis. TEVA's Margin Discussion Adjusted gross margin was 54.6% for the quarter, up 170 basis points (bps) year over year. The rise is mainly driven by higher Austedo revenues, the sale of certain product rights in Europe and the divestment of the business venture in Japan, partially offset by lower Copaxone revenues. Adjusted research & development expenses decreased 9% year over year to $244 million. Selling and marketing expenditure was comparatively flat year over year at $654 million. General and administrative expenses increased 8% from the prior-year level to $305 million. Adjusted operating income rose 7% year over year in the second quarter to $1.13 billion. Adjusted operating margin increased 180 bps to 27.1% in the quarter, mainly due to higher gross profit margin as well as lower operating expenses as a percentage of revenues. Teva expects an adjusted operating margin of 30% by 2027 to be achieved by cost savings and the continued growth of its branded drugs. Teva Pharmaceutical Industries Ltd. Price, Consensus and EPS Surprise Teva Pharmaceutical Industries Ltd. price-consensus-eps-surprise-chart | Teva Pharmaceutical Industries Ltd. Quote TEVA Updates Guidance for 2025 Teva continues to expect its total revenues in 2025 to be in the range of $16.8-$17.2 billion. Teva raised the lower end of its expectation for Austedo from $1.95-$2.05 billion to $2-$2.05 billion. The company also raised its full-year guidance for Ajovy sales from $600 million to the range of $630-$640 million. Uzedy guidance has been raised from $160 million to the range of $190-$200 million in 2025. Copaxone guidance was maintained at $370 million. Teva expects adjusted EPS to be in the range of $2.5-$2.65 per share in 2025 compared with the prior expectation of $2.45-$2.65. The company continues to expect its adjusted operating income to be in the range of $4.3-$4.6 billion in 2025. Adjusted EBITDA was maintained in the range of $4.7-$5 billion. TEVA's Zacks Rank Teva currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Insider
17 hours ago
- Business Insider
'Double Disaster': Boeing Stock (NYSE:BA) Slips On Strike Threat, Trouble for the F-47
Just when you think things might be going well for aerospace stock Boeing (BA), along comes the kind of thing that makes you convinced Boeing is trying to snatch defeat from the jaws of victory. A growing problem for the F-47, and the very real potential of a new strike as early as Monday, are hitting Boeing hard. Investors are reconsidering, and shares dropped nearly 2% in Thursday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. New reports suggest that the engine for the F-47 might be a while in coming. In this case, a 'while' means 'up to two years.' That alone is bad news enough for the project, because if the engine is tardy by a whopping two years, then it becomes entirely possible the whole project will be delayed until after the second Trump administration concludes. The engine was supposed to be ready in the fourth quarter of 2027. That is still a substantial time off, but now, the engine will not arrive until the second quarter of fiscal 2030. A report from Breaking Defense noted, 'Considering the aggressive timeline the Pentagon is pushing to fly the F-47 before the end of President Donald Trump's term, a next-gen engine is likely out of reach for the fighter in the near future.' But that was just the start of the F-47's problems, as another one is likely to rear its ugly head as early as Monday. The other is brewing as we speak in St. Louis, though it should be resolved well before the engine arrives. (Another) Strike Incoming Workers at three different Boeing plants in and around St. Louis may go on strike as early as Monday. Boeing made one more attempt to establish a new contract with the International Machinists and Aerospace Workers union, but that contract was pretty soundly rejected at last report. That set up the union for a week-long 'cooling-off period' that will cool off absolutely no one, and a strike is set to follow from there. So why did the union pass on the latest contracts? Reports note that the issue was not that the St. Louis plant would have received far smaller raises than their Everett equivalents under the new contract, but rather, the biggest issue is a matter of work schedules. Under the new agreement, Boeing would have been allowed to move workers from eight-hour shifts over five days to 10-hour shifts over four days. Some employees would even have been obliged to take on 12-hour shifts, but over three days. Is Boeing a Good Stock to Buy Right Now? Turning to Wall Street, analysts have a Strong Buy consensus rating on BA stock based on 18 Buys and two Holds assigned in the past three months, as indicated by the graphic below. After a 26.66% rally in its share price over the past year, the average BA price target of $256.68 per share implies 15.64% upside potential.
Business Insider
17 hours ago
- Business Insider
First Solar (FSLR) Gets a Buy from Roth MKM
Roth MKM analyst Philip Shen reiterated a Buy rating on First Solar yesterday and set a price target of $225.00. The company's shares closed yesterday at $174.73. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Shen covers the Technology sector, focusing on stocks such as First Solar, Array Technologies, and NEXTracker, Inc. Class A. According to TipRanks, Shen has an average return of 5.1% and a 39.57% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for First Solar with a $210.11 average price target, implying a 20.25% upside from current levels. In a report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $204.00 price target.
